Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
High-rolling investors have positioned themselves bullish on Merck & Co (NYSE:MRK), and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in MRK often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 8 options trades for Merck & Co. This is not a typical pattern.
The sentiment among these major traders is split, with 62% bullish and 37% bearish. Among all the options we identified, there was one put, amounting to $33,529, and 7 calls, totaling $519,512.
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $105.0 to $135.0 for Merck & Co during the past quarter.
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Merck & Co's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Merck & Co's whale activity within a strike price range from $105.0 to $135.0 in the last 30 days.
Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
---|---|---|---|---|---|---|---|---|---|---|---|
MRK | CALL | SWEEP | BULLISH | 07/19/24 | $2.01 | $2.0 | $2.01 | $135.00 | $204.4K | 2.5K | 1.0K |
MRK | CALL | TRADE | BULLISH | 01/17/25 | $25.2 | $24.35 | $25.2 | $105.00 | $126.0K | 5.5K | 2 |
MRK | CALL | SWEEP | BULLISH | 01/17/25 | $10.5 | $10.35 | $10.5 | $125.00 | $62.9K | 2.8K | 62 |
MRK | CALL | TRADE | NEUTRAL | 04/19/24 | $15.75 | $15.35 | $15.57 | $110.00 | $46.7K | 3.1K | 7 |
MRK | PUT | SWEEP | BEARISH | 01/17/25 | $7.45 | $7.35 | $7.45 | $125.00 | $33.5K | 2.4K | 10 |
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
Following our analysis of the options activities associated with Merck & Co, we pivot to a closer look at the company's own performance.
5 market experts have recently issued ratings for this stock, with a consensus target price of $138.0.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Merck & Co with Benzinga Pro for real-time alerts.
Posted In: MRK